Nvidia introduced its BioNeMo Agent Toolkit at the Bio International Convention in San Diego, aiming to turn large language models into autonomous systems for biotech research. The toolkit positions itself as infrastructure for “AI scientists” capable of managing entire biology and chemistry workflows from start to finish.
Kimberly Powell, Nvidia’s vice president of healthcare and life sciences, described the change as a new type of scientific instrument. These tools don’t just observe—they reason, plan, and execute tasks independently. She called it the fastest platform shift the life sciences industry has experienced.
The BioNeMo Agent Toolkit connects generative AI with real-world applications. It turns large language models into domain-specific AI agents capable of executing end-to-end biology and chemistry workflows while optimizing for performance and cost.
Related: Crusoe builds sustainable AI infrastructure
Efficiency drives the design. Powell highlighted that the toolkit reduces computational costs by minimizing LLM calls and GPU usage. “A BioNeMo-enabled agent produces better science while using fewer resources,” she said.
A demonstration showed the toolkit’s potential in protein-binder design for MCL1, a protein tied to tumor survival. Traditionally, this process takes months of expert work. With BioNeMo, an agent can handle the entire pipeline—predicting target structures, generating binders, evaluating docking poses, and ranking candidates—without human input.
The impact on biotech and pharma could be substantial. Powell suggested agents will shorten discovery timelines from years to months or even days.
As digital design accelerates, wet-lab processes become the bottleneck. Powell sees pharma moving toward partnerships that integrate AI labs, tool providers, and platform companies into closed-loop systems, where every experiment refines proprietary models and agents.
Related: Cyera Doubles Valuation to $12B in Five Months
Nvidia’s push into life sciences isn’t new, but the BioNeMo Agent Toolkit unifies the agentic stack for biotech. The open-source approach prevents vendor lock-in, giving companies control over their workflows.
Powell made the ambition clear. “Agentic AI transformed coding. Now the same shift is coming to science.” For biotech leaders, the challenge is adopting the right tools to make it work. Nvidia believes its toolkit provides the foundation many will choose.
Companies like Helion have shown how quickly valuations can rise in emerging tech sectors.
